pemigatinib is a medication used to treat certain types of cancer, specifically locally advanced or metastatic cholangiocarcinoma (bile duct cancer). It generally belongs to a class of drugs called fibroblast growth factor receptor (FGFR) inhibitors. Here’s a brief overview of the action and spectrum of pemigatinib:
Action: pemigatinib works by inhibiting the activity of certain FGFRs, specifically FGFR1, FGFR2, and FGFR3. These receptors are proteins that play a role in cell growth, division, and angiogenesis (formation of new blood vessels). By blocking these receptors, pemigatinib helps to slow down/prevent the growth of cancer cells.
Spectrum: pemigatinib primarily treats cholangiocarcinoma, cancer originating in the bile ducts. It is indicated for patients with locally advanced or metastatic cholangiocarcinoma with a specific genetic alteration known as FGFR2 fusion or rearrangement. This genetic alteration leads to abnormal activation of the FGFR pathway, making the cancer cells more dependent on FGFR signaling for growth.
It’s important to note that pemigatinib is prescribed by healthcare professionals. Its use should be guided by a comprehensive understanding of the patient’s condition, medical history, and genetic profile. The dosing, administration, and potential side effects of pemigatinib may vary depending on individual circumstances.